^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

C1As

1m
ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma (clinicaltrials.gov)
P1/2, N=20, Active, not recruiting, Ciusss de L'Est de l'Île de Montréal | Trial primary completion date: Sep 2021 --> Oct 2023
Trial primary completion date
|
CD34 (CD34 molecule)
|
Chr del(17p) • Chr t(4;14) • Chr t(14;16) • Chr t(14;20) • C1As
|
cyclophosphamide • melphalan • ECT-001-CB
5ms
Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients (clinicaltrials.gov)
P2, N=40, Completed, Maisonneuve-Rosemont Hospital | Active, not recruiting --> Completed
Trial completion
|
HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
|
Chr del(17p) • Chr t(4;14) • Chr t(14;16) • Chr t(14;20) • C1As
|
bortezomib • melphalan
8ms
Concomitant deletion of the short arm (Del 1p13.3) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma. (PubMed, Cancer)
The PFS and OS of patients with combined abnormalities of del (1p13.3)/1q21gain or amp was significantly worse compared to del(1p13.3) alone and 1q21gain or 1q21 amp alone, which identifies a subset of patients with poor clinical outcomes.
Clinical data • Journal
|
AHCYL1 (Adenosylhomocysteinase Like 1)
|
C1As
10ms
Pathogenesis, clinical characteristics and personalized managements of multiple myeloma with chromosome 1 abnormalities. (PubMed, Leuk Lymphoma)
However, more effective therapeutic approaches are still needed to overcome the negative impact of C1As. Therefore, we summarize the prevalence, pathogenesis, clinical significance and present therapeutic condition of C1As in MM, and attempt to conclude the precise and personalized management for patients with C1As.
Review • Journal
|
C1As
2years
ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma (clinicaltrials.gov)
P1/2, N=20, Active, not recruiting, Ciusss de L'Est de l'Île de Montréal | Recruiting --> Active, not recruiting
Enrollment closed
|
CD34 (CD34 molecule) • CD27 (CD27 Molecule)
|
Chr del(17p) • C1As
|
cyclophosphamide • melphalan • ECT-001-CB
2years
ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma (clinicaltrials.gov)
P1/2, N=20, Recruiting, Ciusss de L'Est de l'Île de Montréal | Trial completion date: Mar 2024 --> Sep 2025 | Trial primary completion date: Mar 2022 --> Sep 2021
Trial completion date • Trial primary completion date
|
CD34 (CD34 molecule) • CD27 (CD27 Molecule)
|
Chr del(17p) • C1As
|
melphalan • ECT-001-CB
over2years
Concomitant Deletion of Short Arm (del 1p) and Amplification or Gain (1q21) of Chromosome 1 By Fluorescence in Situ Hybridization (FISH) Is Associated with Poor Clinical Outcome (ASH 2021)
Concomitant del 1p with 1q21 gain and /or amp was present in 8% of patients. The PFS and OS of patients with combined del1p/1q21gain abnormalities was significantly worse compared to del 1p alone and 1q21 gain alone and thus identifies a subset of patients with poor clinical outcome.
Clinical • Clinical data
|
AHCYL1 (Adenosylhomocysteinase Like 1)
|
C1As
over2years
Molecular Features and Clinical Outcomes of Extramedullary Plasmacytomas (ASH 2021)
Our data suggest that KRAS / NRAS / BRAF mutations may play an important role in the development of EMD. These and other associated molecular abnormalities portend a poorer prognosis and may provide novel therapeutic insights.
Clinical • Clinical data
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • ARID1A (AT-rich interaction domain 1A)
|
TP53 mutation • BRAF mutation • NRAS mutation • ATM mutation • ARID1A mutation • TP53 deletion • C1As
over2years
Whole-genome optical mapping of bone-marrow myeloma cells reveals association of extramedullary multiple myeloma with chromosome 1 abnormalities. (PubMed, Sci Rep)
Our pilot study revealed an association of chromosome 1 abnormalities in bone marrow myeloma cells with extramedullary progression. Optical mapping showed the potential for refining the complex genomic architecture in MM and its phenotypes.
Journal
|
SDC1 (Syndecan 1)
|
C1As